US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Gastric Adenocarcinoma
Basilea Pharmaceutica
Basilea Pharmaceutica drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Allschwil, CH HQ
2000 Founded
246 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Allschwil, CH
- Founded
- 2000
- Employees
- 246
- Programs
- 2
- Drugs
- 3
- Patents
- 25
Basilea Pharmaceutica pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Basilea Pharmaceutica drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Basilea Pharmaceutica in public FDA and regional records.
-
Development asset linked to Basilea Pharmaceutica in public FDA and regional records. Molecular target: GPI-anchored wall transfer protein 1.
- Target
- GPI-anchored wall transfer protein 1
- Mechanism
- GPI-anchored wall transfer protein 1 inhibitor